FDA Approved: VYONDYS 53 — Supplemental Application (Sarepta Therapeutics, Inc.)

View source ↗

Summary

FDA approved a supplemental application for VYONDYS 53 (golodirsen) from Sarepta Therapeutics, Inc. The approval pertains to Duchenne muscular dystrophy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Duchenne Muscular Dystrophy

Drugs mentioned

• VYONDYS 53 (golodirsen)

Snippet

SUPPL AP for VYONDYS 53 (GOLODIRSEN)